Peptide Database

CJC-1295 with DAC · DAC:GRF

CJC-1295 is a modified GHRH analog with a Drug Affinity Complex (DAC) that binds to serum albumin, dramatically extending its half-life compared to native GHRH. It produces sustained elevation of GH and IGF-1 levels over days rather than hours. Research focuses on body composition improvements, muscle growth, and fat loss through prolonged GH axis stimulation.

C₁₅₂H₂₅₂N₄₂O₄₂S · 3647.28 Da

Growth Hormone-Releasing Hormone · Somatoliberin

GHRH is the endogenous 44-amino-acid hypothalamic peptide that drives the pulsatile secretion of growth hormone from the anterior pituitary. Native GHRH acts through GHRHR, stimulating GH gene transcription and secretion. It has a very short half-life in vivo, making it impractical as a therapeutic — which drove the development of modified analogs like sermorelin, CJC-1295, and tesamorelin. Research into GHRH receptor signaling underpins the entire GH secretagogue drug class.

Long R3 IGF-1 · Insulin-like Growth Factor 1 Long R3

IGF-1 LR3 is a modified version of Insulin-like Growth Factor-1 with an arginine substitution and 13-amino-acid N-terminal extension, which reduces binding to IGF-binding proteins and extends its half-life. It promotes muscle cell hyperplasia and hypertrophy by activating the PI3K/AKT/mTOR pathway. Research explores its role in muscle wasting, recovery from injury, and anabolic signaling.

CJC-1295 without DAC · Modified GRF 1-29

Mod GRF 1-29 is a modified version of GHRH(1-29) with four amino acid substitutions that increase stability and half-life without the DAC albumin-binding component. It produces a natural, pulsatile GH release and is commonly paired with GHRPs (like Ipamorelin) for a synergistic GH pulse. Its shorter duration preserves natural pituitary feedback mechanisms.

Sandostatin · SMS 201-995

Octreotide is a synthetic 8-amino-acid somatostatin analog with a much longer half-life than native somatostatin. FDA-approved for acromegaly, carcinoid syndrome, VIPomas, and variceal bleeding, it is also used off-label for Cushing's disease, thyroid cancer, and refractory diarrhea. Long-acting release (LAR) formulations allow monthly dosing. It is among the most clinically important peptide drugs in endocrinology.

PEGylated Mechano Growth Factor

PEG-MGF is a PEGylated (polyethylene glycol-modified) form of Mechano Growth Factor, designed to dramatically extend its biological half-life from minutes to days while preserving activity. PEGylation allows systemic delivery and sustained satellite cell activation without the need for local injection. Research shows enhanced muscle hypertrophy signaling compared to unmodified MGF.

SRIF · Somatotropin Release-Inhibiting Factor

Somatostatin is a 14-amino-acid cyclic peptide and the primary endogenous inhibitor of growth hormone secretion. It also inhibits insulin, glucagon, gastrin, cholecystokinin, and secretin release, slows GI motility, and reduces splanchnic blood flow. Its short half-life drove the development of longer-acting analogs (octreotide, lanreotide) used clinically for acromegaly, neuroendocrine tumors, and GI bleeding.